#None #Securities Class Action #Investor Alert #NowRx

NowRx Inc. Class Action Lawsuit: An Investor's Guide

In a significant turn of events for shareholders, Squitieri & Fearon LLP along with Moore Law PLLC have announced the opportunity for investors in NowRx, Inc. to lead a class action lawsuit. This comes in light of serious allegations surrounding the company’s financial disclosures and potential mismanagement.

Background on NowRx Inc.

Founded in 2016 and headquartered in Mountain View, California, NowRx is a pharmacy service that utilizes technology to provide same-day prescription deliveries along with telehealth services. The firm recently engaged in a securities offering, promoting $10.50 shares in a Series C Preferred Stock offering starting in September 2021. However, by late 2022, the company faced significant issues that prompted an acquisition by Alto Pharmacy, leading to a total loss of investment for Series C stockholders.

Lawsuit Details

The class action lawsuit was initiated on November 4, 2025, following allegations that the company did not adequately disclose crucial information about its financial state. According to the lawsuit, pivotal details surrounding NowRx's financial struggles were withheld from investors including:
1. Non-disclosure of adverse facts regarding their overall financial condition.
2. Ignoring signs of impending bankruptcy or operational insolvency.
3. Failing to inform investors about hiring an investment bank to explore options for a significant capital raise or a sale of the business.
4. Misleading valuations indicating a $3.55 share price by an investment bank, contrasting sharply with the offered shares at a price of $10.50.

Who Can Join the Class Action?

The lawsuit invites any party who acquired NowRx securities between February 1, 2022, and November 5, 2022, to step forward by the deadline of January 23, 2026. By qualifying as a lead plaintiff, investors can help steer the legal proceedings on behalf of others impacted. This approach ensures that the individuals with the most at stake can take charge in pursuing restitution for the group.

The Process for Becoming a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, members of the purported class can apply to serve as the lead plaintiff. Key criteria include:

• - Having the greatest financial stake in the lawsuit.
• - Representing the class in a typical and adequate manner.

Essentially, it's crucial for individual investors to be proactive, particularly if they suffered significant losses during the outlined period. This initiative ensures that investors' voices are adequately represented throughout the litigation.

Contact Information

If you think you qualify to act as a lead plaintiff or would like further details on the lawsuit, you can reach out to:

• - Lee Squitieri or Fletcher Moore at (212) 709-8245 or via email at [email protected] and [email protected].

Conclusion

This class action lawsuit against NowRx, Inc. shines a spotlight on the importance of transparency and accountability in corporate practices, especially in complex sectors like pharmaceuticals. For investors negatively impacted by the handling of their investments, engaging with this lawsuit might be a crucial step toward securing justice and recovering losses. As always, diligent understanding and responsiveness to communications from regulatory and legal entities are vital for safeguarding financial interests.